The effect of sorafenib (Nexavar) on 111-indium labeled chimeric monoclonal antibody G250 [WX-G250] or 111-indium labeled bevacizumab (Avastin) uptake in patients with clear cell RCC [renal cell carcinoma] (ccRCC)
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 22 Feb 2012 Planned End Date changed from 1 Dec 2008 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 27 Feb 2008 New trial record.